New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices.

Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation. Burdensome regulation also delays drug development, and this can translate into thousands of life-years lost. We ne...

Full description

Bibliographic Details

Published in:	Current Oncology Vol. 31; no. 5; pp. 2453 - 2481
Main Authors:	Stewart, David J., Bradford, John-Peter, Sehdev, Sandeep, Ramsay, Tim, Navani, Vishal, Rawson, Nigel S. B., Jiang, Di Maria, Gotfrit, Joanna, Wheatley-Price, Paul, Liu, Geoffrey, Kaplan, Alan, Spadafora, Silvana, Goodman, Shaun G., Auer, Rebecca A. C., Batist, Gerald
Format:	Journal Article
Published:	MDPI May2024
Online Access:	View this record in EBSCOhost